Q4 EPS Forecast for MIRA Pharmaceuticals Lowered by Analyst

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) – Investment analysts at Zacks Small Cap dropped their Q4 2024 earnings per share (EPS) estimates for shares of MIRA Pharmaceuticals in a research note issued to investors on Thursday, December 19th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings per share of ($0.29) for the quarter, down from their prior estimate of ($0.19). The consensus estimate for MIRA Pharmaceuticals’ current full-year earnings is ($0.60) per share. Zacks Small Cap also issued estimates for MIRA Pharmaceuticals’ FY2026 earnings at ($0.54) EPS.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04.

A number of other equities research analysts have also recently weighed in on the company. Rodman & Renshaw started coverage on MIRA Pharmaceuticals in a research note on Monday, September 30th. They issued a “buy” rating and a $17.00 price objective for the company. RODMAN&RENSHAW upgraded MIRA Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th.

MIRA Pharmaceuticals Stock Performance

MIRA Pharmaceuticals stock opened at $1.06 on Monday. The company has a market capitalization of $17.55 million, a PE ratio of -1.89 and a beta of 1.93. MIRA Pharmaceuticals has a fifty-two week low of $0.51 and a fifty-two week high of $5.01. The firm has a 50 day moving average price of $1.36 and a 200 day moving average price of $1.37.

Hedge Funds Weigh In On MIRA Pharmaceuticals

A hedge fund recently raised its stake in MIRA Pharmaceuticals stock. Suncoast Equity Management raised its position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 125.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,000 shares of the company’s stock after acquiring an additional 50,000 shares during the quarter. Suncoast Equity Management owned approximately 0.61% of MIRA Pharmaceuticals worth $117,000 as of its most recent SEC filing. 35.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at MIRA Pharmaceuticals

In other MIRA Pharmaceuticals news, CEO Erez Aminov sold 55,410 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $1.39, for a total transaction of $77,019.90. Following the sale, the chief executive officer now owns 1,105,790 shares in the company, valued at $1,537,048.10. This represents a 4.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.65% of the stock is currently owned by corporate insiders.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.